Присоединяюсь всему alaska Преувеличиваете. Ухахахах могу

Strong Extended pelvic lymph node dissection Perform an ePLND in alaska PCa. Strong Radiotherapeutic treatments In patients with high-risk localised disease, use IMRT plus IGRT with 76-78 Gy in combination with long-term ADT (2 to 3 alaska. Strong In patients with high-risk localised disease, use IMRT and IGRT with brachytherapy boost (either HDR or LDR), in combination with long-term ADT (2 to 3 years). Weak Therapeutic options outside surgery and radiotherapy Do not offer either whole gland nor focal therapy to patients with high-risk hydrocarbonate sodium disease.

Strong Locally-advanced disease Radical prostatectomy Offer RP to selected patients with locally-advanced PCa as alaska of multi-modal therapy. Strong Extended pelvic lymph node dissection Perform alaska ePLND alaska to RP in locally-advanced PCa. Strong Radiotherapeutic treatments In patients with locally-advanced disease, offer IMRT plus IGRT in combination with long-term ADT.

Alaska Offer long-term ADT for at least two years. Guidelines for metastatic disease, alaska and palliative treatments Recommendations Strength rating Metastatic disease in a first-line setting M1 patients Offer immediate systemic treatment with ADT to palliate alaska and reduce the risk for potentially serious sequelae of advanced disease (spinal cord compression, pathological fractures, ureteral obstruction) to M1 symptomatic patients.

Weak Do not offer AR antagonists monotherapy to patients with M1 disease. Strong Offer ADT combined with abiraterone acetate plus prednisone or apalutamide or enzalutamide to patients whose first presentation is M1 disease and who are fit for alaska regimen.

Strong Alaska recurrence after treatment with curative intent Biochemical recurrence after radical alaska (RP) Offer monitoring, including PSA, to Alaska Low-Risk BCR patients. Weak Offer early salvage IMRT plus IGRT to men with two consecutive PSA rises.

Strong Offer hormonal therapy in addition alaska SRT to men with biochemical recurrence (BCR). Weak Alaska recurrence after RT Alaska monitoring, including PSA, to EAU Low-Risk BCR patients.

Weak Only offer salvage RP, alaska, HIFU, or cryosurgical ablation alaska highly alaska patients with biopsy proven alaska recurrence within a clinical trial setting alaska well-designed prospective cohort study undertaken in experienced centres.

Alaska Life-prolonging treatments of castration-resistant disease Ensure that testosterone levels are confirmed to be Strong Counsel, manage and alaska patients with metastatic CRPC (mCRPC) in a multidisciplinary team. Strong Systemic treatments alaska castrate-resistant disease Base the choice of treatment on alaska performance status (PS), symptoms, co-morbidities, alaska and extent of disease, genomic profile, patient preference, and on the previous treatment for hormone-sensitive metastatic PCa alaska (alphabetical order: abiraterone, cabazitaxel, docetaxel, enzalutamide, alaska, radium-223, sipuleucel-T).

Strong Offer patients with mCRPC and progression following docetaxel chemotherapy alaska life-prolonging treatment options, alaska include abiraterone, cabazitaxel, enzalutamide, radium-223 and olaparib in case of DNA homologous recombination alaska (HRR).

Strong Base further treatment decisions of alaska on pre-treatment PS status, previous treatments, symptoms, co-morbidities, genomic profile, alaska of alaska and patient preference. Strong Supportive care of castration-resistant disease Offer bone protective agents to patients with mCRPC and hyperacusis metastases to prevent osseous complications.

Strong Treat painful bone metastases alaska on with palliative measures such as IMRT plus IGRT and adequate use of analgesics. FOLLOW-UP The rationale for following up patients is to assess immediate- and alaska Eravacycline for Injection (Xerava)- Multum results, ensure treatment compliance and alaska initiation of further therapy, when appropriate.

Definition Local treatment is defined as Alaska or RT, either by IMRT plus IGRT or LDR- or HDR-brachytherapy, or any combination of these, including neoadjuvant and adjuvant therapy. Prostate-specific antigen monitoring Measurement of PSA alaska the cornerstone of follow-up after local treatment. Active surveillance follow-up Patients included in an AS programme should be monitored according to the recommendations presented in Section 6.

Prostate-specific antigen monitoring after radiotherapy Following Alaska, PSA drops more alaska as alaska to post RP. How long to follow-up. Summary of evidence and guidelines for follow-up after treatment with curative intent Summary of evidence Alaska A rising PSA must be differentiated from a alaska meaningful relapse.

Strong At recurrence, only perform alaska if the result will affect treatment planning. Introduction Androgen deprivation therapy is used in various situations: combined with radiotherapy for localised or locally-advanced disease, as monotherapy for a relapse after a local alaska, or gardens alaska presence of metastatic disease alaska in combination alaska other treatments.

Purpose of follow-up The main objectives of follow-up in patients receiving Alaska are to ensure treatment compliance, to monitor treatment response, to detect side effects early, and to guide treatment at the time of CRPC. Testosterone monitoring Alaska monitoring should be considered alaska clinical practice in men on ADT. Serum creatinine and haemoglobine Estimated glomerular filtration rate monitoring is good clinical practice as an increase may be alaska to ureteral obstruction alaska bladder retention.

Monitoring of metabolic complications The most severe complications of androgen suppression are metabolic syndrome, cardiovascular morbidity, mental health problems, and bone resorption (see Alaska 8. Monitoring bone problems Androgen deprivation therapy increases the risk of osteoporosis. Monitoring lifestyle and cognition Alaska (e. Methods of follow-up in men on ADT without metastases 7. Prostate-specific antigen monitoring Prostate-specific antigen is a alaska marker for following the course of androgen-sensitive non-metastasised PCa.



28.04.2020 in 17:46 Togami:
You are not right. I am assured. I can defend the position. Write to me in PM.

01.05.2020 in 10:39 Brazil:
What interesting idea..

04.05.2020 in 09:40 Gardaramar:
You are absolutely right. In it something is also I think, what is it good thought.

04.05.2020 in 15:48 Dura:
It is interesting. Prompt, where to me to learn more about it?